ERBB2 and cancer: Although physiologic age should guide treatment receipt both in low-risk cancers, like stage I–II HR+/HER-2− disease, and high-risk cancers, like HER-2+ and TNBCs, in this particular cohort, there was not a clear signal that this was common practice.